Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial

• DOI: 10.1016/j.clnu.2023.07.002
• Publication Date: 2023-07-19T06:54:37Z
• Authors: Peder L. Myhre; Trygve Berge; Are A. Kalstad; Sjur H. Tveit; Kristian Laake; Erik B. Schmidt; Svein Solheim; Harald Arnesen; Ingebjørg Seljeflot; Arnljot Tveit
• Keywords: Male; Eicosapentaenoic acid; Omega-3 PUFA; Docosahexaenoic Acids; Myocardial Infarction; 610; Atrial fibrillation; 3. Good health; Docosahexaenoic acid; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Atrial Fibrillation; Dietary Supplements; Humans; Female

Recent randomized clinical trials have raised concerns regarding potential off target adverse effects from supplementation of n-3 polyunsaturated fatty acids (PUFA) on atrial fibrillation (AF) risk. We aimed to assess risk and mediators AF 'micro-AF' PUFA in post-myocardial infarction (MI) patients.In the OMEMI trial, 70-82 y. o. patients with a recent MI were 1.8 g/day eicosapentaenoic-/docosahexaenoic acid (EPA/DHA) or placebo (corn oil) for two years. New-onset was recorded by detection screening Zenicor thumb-ECG (adjudicated blinded investigators). Serum EPA DHA measured at baseline study end.At baseline, 759 1014 (75%) had no history. These aged 75 ± 4 years 71% male. During follow-up, 43 developed new-onset (39 clinically-detected screening). In addition, 27 episodes micro-AF, yielding total 70 'micro-AF'. group 46 (11.9%) AF/'micro-AF' (28 AF, 18 'micro-AF') 24 (6.5%) AF/micro-AF (15 9 micro-AF); HR 1.90 (95%CI 1.16-3.11), P = 0.011. Changes serum (but not DHA) mediated effect risk, explaining 65% association.Supplementation post increases seems be an important mediator treatment AF.OMEMI Study; ClinicalTrails.gov identifier: NCT0184194.